RT Journal Article
SR Electronic
T1 Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.26.22274275
DO 10.1101/2022.04.26.22274275
A1 Sena, Laura A
A1 Kumar, Rajendra
A1 Sanin, David E
A1 Thompson, Elizabeth A
A1 Rosen, D Marc
A1 Dalrymple, Susan L
A1 Antony, Lizamma
A1 Yang, Yuhan
A1 Gomes-Alexandre, Carolina
A1 Hicks, Jessica L
A1 Jones, Tracy
A1 Bowers, Kiara A.
A1 Eskra, Jillian N
A1 Meyers, Jennifer
A1 Gupta, Anuj
A1 Skaist, Alyza
A1 Yegnasubramanian, Srinivasan
A1 Luo, Jun
A1 Brennen, W Nathaniel
A1 Kachhap, Sushant K
A1 Antonarakis, Emmanuel S
A1 De Marzo, Angelo M
A1 Isaacs, John T
A1 Markowski, Mark C
A1 Denmeade, Samuel R
YR 2022
UL http://medrxiv.org/content/early/2022/04/28/2022.04.26.22274275.abstract
AB Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological androgen (SPA), entitled Bipolar Androgen Therapy (BAT), can result in tumor regression and clinical benefit for patients with castration-resistant prostate cancer [1–5]. However, predictors and mechanisms of response and resistance have been ill-defined. Here we show that growth inhibition of prostate cancer models by SPA requires high androgen receptor (AR) abundance and activity and is driven in part by downregulation of MYC. Using matched sequential patient biopsies, we show that high pre-treatment AR activity predicts downregulation of MYC, clinical response, and prolonged progression-free and overall survival for patients on BAT. BAT induced strong downregulation of AR in all patients, which is shown to be a primary mechanism of acquired resistance to SPA. Acquired resistance can be overcome by alternating SPA with the AR inhibitor enzalutamide, which induces adaptive upregulation of AR and re-sensitizes prostate cancer to SPA. This work identifies a predictive biomarker of response to BAT and supports a new treatment paradigm for prostate cancer involving alternating between AR inhibition and activation.Competing Interest StatementConflicts of Interest: ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Lilly, Bayer, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of an AR-V7 biomarker technology that has been licensed to Qiagen. SRD has received research funding to his institution from Astellas. AMD is a paid consultant/advisor to Merck and Cepheid and has received research funding from Janssen and Myriad for unrelated work. SY receives research funding to his institution from Bristol-Myers Squibb/Celgene, Janssen, and Cepheid for unrelated work, and has served as a consultant for Cepheid, and owns founder's equity in Brahm Astra Therapeutics and Digital Harmonic. MCM is a paid consultant to Clovis and Exelixis. Other authors declare no conflicts of interest.Clinical TrialNCT03554317Funding StatementThis work was supported by Department of Defense early investigator awards to LAS and RK (W81XWH2010079 and PC210095, respectively), a JHU Clinician-Scientist award to LAS, a Prostate Cancer Foundation young investigator award to RK, an NIH/NCI SPORE prostate cancer grant (P50CA058236) to SRD, a Prostate Cancer Foundation challenge award to ESA and SKK, and W81XWH1910724 and 1R01CA243184-01A1 to SKK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Johns Hopkins University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors